why choose us

First received: January 20, 2023

Clinical Trial: Immunomodulatory Effects of PCSK9 Inhibition

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Atherosclerotic Cardiovascular Disease

Study Type: OBSERVATIONAL


Official Title: ImmuNomodulatory EffectS of PCSK9 Inhibition: A TaRgeted Molecular Imaging AppRoach

Brief Summary: Cardiovascular disease (CVD) represents the leading cause of death worldwide.While medications, such as statins, significantly reduce atherosclerotic CVD (ASCVD) risk by lowering low density lipoprotein levels, they may also have pleiotropic effects on inflammation.The immunomodulatory effects of these medications are relevant to ASCVD risk reduction given that inflammation plays a central role in atherosclerotic plaque formation (atherogenesis) and influences the development of vulnerable plaque…

Read more